- Test Kits & Reagents
- Consumables
Noninvasive Cancer Diagnostics Market size was valued at USD 193.2 billion in 2021, growing at a CAGR of 7.4% from 2022 to 2028. The noninvasive technique is a procedure that does not require insertion of an instrument through the skin. With the advancements in the technology, there are various treatment procedures that are being used. The advent of the modern diagnostic techniques helps in the detection of cancer. The noninvasive techniques play a vital role in the diagnosis of cancer replacing the invasive tests. Noninvasive Cancer Diagnostics Market is a method of diagnosing a condition that does not require or requires only minor body incisions. These techniques include determining genetic structure, biomarkers, alterations in molecular biology, and imaging technologies, among others. Cancer is a disease caused by a genetic change in the cells, resulting in uncontrolled development and the formation of a tumor-like structure. Imaging is the primary method of cancer detection, but it does not allow for genetic access; on the other hand, biopsies that allow for genetic access are complicated and difficult to do repeatedly during cancer diagnosis and treatment. As a result, innovative approaches such as molecular diagnostics, serum-based immunoassays, and chemical tests have been developed to identify chemical components in the body, particularly from blood and urine.
Key Development: In February 2020, Biocare Medical launched its seven new IVD IHC antibody markers, especially for clinical diagnostics and research applications, focusing on various immuno-oncology markers, vital in aiding early-stage cancer patient treatment and drug developments. This launch will help the company to enhance its product portfolio in the market.Noninvasive Cancer Diagnostics Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.4%
Largest Market
North America
Fastest Growing Market
North America
Noninvasive Cancer Diagnostics Market Dynamics Drivers
Increase in the prevalence of chronic diseases such as cancer is the key factor attributed for the growth of the noninvasive cancer diagnostics market. The technological advancements play a vital role in the development of the noninvasive techniques. Rising demand for the noninvasive and minimally invasive diagnosis is adding fuel for the growth of the market. The growing geriatric population along with growing health issues and rising awareness among the patient population regarding various treatment options is boosting the growth of the noninvasive cancer diagnostics market. The initiation taken by the government and non-profitable organizations to create awareness regarding the early diagnosis of the disease is anticipated to drive the growth of the noninvasive cancer diagnostics market.
North-America Got Significant Share
Noninvasive Cancer Diagnostics Market
North America dominates the market over the forecasted period owing to the availability of advanced technologies in the region. On the other hand, Asia-Pacific is projected to observe a rapid and lucrative growth rate during the forecast period owing to the rising prevalence of cancer patients and increasing awareness about minimal invasive equipment for diagnosis along with growing government initiatives towards efficient healthcare diagnosis and advanced technology.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Noninvasive Cancer Diagnostics Market Segmentation
By Product
By Application
- Lung Cancer
- Breast Cancer
- Solid tumors
- Blood cancer
- Others
By technique
- Immunochemistry/Immunoassay
- Molecular Diagnostics
- Clinical Chemistry
- Others
distribution channel
- Hospitals
- Diagnostic Centers
- Oncology Centers
- Others
LOCATION
Geography
Frequently Asked Questions
The major factors driving the market growth are the increasing prevalence of various types of cancer, such as lung cancer, breast cancer, and more. Also, the increasing geriatric population and increasing awareness about the diagnosis procedures will be anticipated to expand the market of noninvasive cancer diagnostics.
The high cost of treatment and stringent regulatory policies are some restraining factors that obstruct the market’s growth.
The global noninvasive cancer diagnostics market size is expected to be valued at USD 193.2 billion in 2021.
Investment and acquisition are the two key strategies opted for prominent companies in the market.
[urltag url='request-table-of-content']
- Digene Corporation (U.S.)
- Gen-Probe Incorporated (U.S.)
- IVDiagnostics, Inc. (U.S.)
- A&G Pharmaceutical, Inc. (U.S.)
- Affymetrix Inc. (U.S.)
- AVIVA Biosciences Corporation (U.S.)
- BIOVIEW Inc. (U.S.)
- Laboratory Corporation of America Holdings (LabCorp) (U.S.)
- Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)